Update shared on 04 Dec 2025
Fair value Increased 5.56%Analysts have raised their price target for Fisher & Paykel Healthcare by roughly NZ$2. This reflects expectations of slightly higher long term profitability, modestly lower growth assumptions, and a marginally higher discount rate.
What's in the News
- Directors approved an increased interim dividend of 19.0 cents per share, up from 18.5 cents a year earlier, with payment scheduled for 16 December 2025 and a record date of 4 December 2025 (company announcement).
- Full year 2025 guidance was raised, with operating revenue now expected between approximately $2.17 billion and $2.27 billion, up from $2.15 billion to $2.25 billion previously (company guidance).
- The company now forecasts full year 2025 net profit after tax in the range of approximately $410 million to $460 million, compared with prior guidance of $390 million to $440 million (company guidance).
Valuation Changes
- Fair Value Estimate has risen slightly, increasing from NZ$37.26 to NZ$39.33 per share.
- Discount Rate has edged up marginally, from 7.76% to 7.79%, implying a slightly higher required return.
- Revenue Growth has been revised down modestly, from 11.58% to 11.20% per year.
- Net Profit Margin has increased slightly, from 21.22% to 22.13%, reflecting expectations of improved profitability.
- Future P/E multiple has decreased modestly, from 45.78x to 44.32x, indicating a slightly lower valuation multiple applied to earnings.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.